Literature DB >> 9402379

Group B streptococcal meningitis in adults: report of twelve cases and review.

P Domingo1, N Barquet, M Alvarez, P Coll, J Nava, J Garau.   

Abstract

Group B streptococcus (GBS) is the leading etiologic agent of bacterial meningitis and sepsis during the neonatal period, but it is an infrequent cause of meningitis in adults. We report 12 episodes of group B streptococcal meningitis in adults and review 52 cases reported in the literature. A total of 24 men and 40 women were included in the study; the mean age (+/- SD) was 49.2 +/- 20.5 years (range, 17-89 years). All the patients had cerebrospinal fluid cultures positive for GBS. Eighty-six percent of the patients had comorbid conditions, 50% had a distant focus of infection, and blood cultures yielded GBS for 78.7%. The overall case-fatality rate was 34.4% (22 patients). Factors associated with a poor outcome were advanced mean age (+/- SD) (61.5 +/- 17.4 years vs. 42.8 +/- 19.2 years; P = .0003) and the presence of complications on admission (P = .0001). Seven percent of survivors had neurological sequelae. Group B streptococcal meningitis in adults has become increasingly frequent in recent years; it tends to occur in patients with severe underlying conditions and is associated with a high case-fatality rate. Factors associated with a poor prognosis are advanced age and the occurrence of neurological and extraneurological complications.

Entities:  

Mesh:

Year:  1997        PMID: 9402379     DOI: 10.1086/516094

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  30 in total

Review 1.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

2.  Identification of a Streptococcus agalactiae serotype III subtype 4 clone in association with adult invasive disease in Hong Kong.

Authors:  Margaret Ip; Edmund S C Cheuk; Michelle H Y Tsui; Fanrong Kong; T N Leung; Gwendolyn L Gilbert
Journal:  J Clin Microbiol       Date:  2006-09-27       Impact factor: 5.948

3.  Streptococcus agalactiae serotype Ib as an agent of meningitis in two adult nonpregnant women.

Authors:  E R Martins; C Florindo; F Martins; I Aldir; M J Borrego; L Brum; M Ramirez; J Melo-Cristino
Journal:  J Clin Microbiol       Date:  2007-09-19       Impact factor: 5.948

4.  Group B streptococcal meningitis in a previously healthy man.

Authors:  Lucy Qian Li; Sanjay Cheema; Nupur Goel
Journal:  BMJ Case Rep       Date:  2016-01-12

5.  Community-acquired meningitis caused by beta-haemolytic streptococci in adults: a nationwide population-based cohort study.

Authors:  Nicolai Kjærgaard; Jacob Bodilsen; Ulrik Stenz Justesen; Henrik Carl Schønheyder; Christian Østergaard Andersen; Svend Ellermann-Eriksen; Esad Dzajic; Ming Chen; Jens Kjølseth Møller; Ram Benny Dessau; Niels Frimodt-Møller; Jens Otto Jarløv; Henrik Nielsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-22       Impact factor: 3.267

6.  Dominance of serotype Ia among group B Streptococci causing invasive infections in nonpregnant adults in Portugal.

Authors:  E R Martins; J Melo-Cristino; M Ramirez
Journal:  J Clin Microbiol       Date:  2012-01-04       Impact factor: 5.948

7.  A case of postpartum Group B streptococcal meningitis.

Authors:  Kylie Gayford; Ana McCarthy; William M Hague
Journal:  Obstet Med       Date:  2011-11-22

Review 8.  Methods of rapid diagnosis for the etiology of meningitis in adults.

Authors:  Nathan C Bahr; David R Boulware
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

9.  CT and MR imaging features of pyogenic ventriculitis.

Authors:  M B Fukui; R L Williams; S Mudigonda
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

10.  Bacterial meningitis: epidemiology, pathogenesis and management update.

Authors:  Yuliya Nudelman; Allan R Tunkel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.